Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease

Chang, Xuting; Zhang, Jie; Li, Shangru; Wu, Pengxia; Wang, Rui; Zhang, Chongfan; Wu, Ye

doi:10.1016/j.msard.2023.104571

Cited by 7 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatments commonly used in the prevention of MOGAD relapses are rituximab, azathioprine, mycophenolate mofetil, tocilizumab, and intravenous immunoglobulins. A recent metaanalysis of 41 studies (3 prospective, 1 ambispective, 37 retrospective) evaluating efficacy of MOGAD-associated treatments found that the proportions of patients free of relapse were 65% [95% confidence interval (CI): 49%-82%] on azathioprine, 73% (95% CI: 62%-84%) on mycophenolate mofetil, 66% (95% CI: 55%-77%) on rituximab, 79% (95% CI: 66%-91%) on IVIG, and 93% (95% CI: 54%-100%) on tocilizumab (31).…”

Section: Chronic Management Of Mogad Disease Modifying Treatmentsmentioning

confidence: 99%

Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease

2023

View full text Add to dashboard Cite

Transverse myelitis (TM) is the second most common presentation of myelin oligodendrocyte antibody-associated disease (MOGAD), occurring in approximately 26% of affected patients. The diagnosis may be complicated by the lack of diagnostic specificity of low titers of MOG antibody in serum, fluctuation in seropositivity overtime, including initially normal MRI in up to 10% of patients, and in many instances complete resolution of radiological abnormalities when MRI is done in a significantly delayed fashion. The use of preventive disease modifying treatments is limited by the uncertainty whether the disease process will remain monophasic or become relapsing, as well as by the lack FDA approved treatments. In this review, we discuss clinical, radiological and cerebrospinal fluid (CSF) characteristics, including the significance of MOG titers and changes in the seropositivity status for the diagnosis of MOGAD-associated TM, its radiological features and management options, highlighting the data on the risk of relapses associated with TM at presentation and the need for further randomized clinical trials to empower effective treatment algorithms.

show abstract

Section: Chronic Management Of Mogad Disease Modifying Treatmentsmentioning

confidence: 99%

Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease

2023

View full text Add to dashboard Cite

show abstract

“…또한, 연간재발률(annualized relapse ratio)을 약 1.58회 감소시키는 것으로 나타났다. 1,21,32,38,39,44,45 하지만 아자 티오프린 치료 후 EDSS 점수는 치료 전과 비교하여 유의한 변 화가 없었다.…”

Section: 아자티오프린(Azathioprine)unclassified

“…재발이 나타난 MOGAD에서 미코페놀레이트 모 페틸을 사용할 경우 약 47-73% 환자에서 재발을 방지할 수 있었 고, 연간재발률 또한 약 1.32회 감소하였다. 21,31,38,39,45…”

Section: 미코페놀레이트 모페틸(Mycophenolate Mofetil)unclassified

National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Kwon,

Kim,

Kim

et al. 2023

J Mult Scler Neuroimmunol

View full text Add to dashboard Cite

Background: The emergence of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), defined by the presence of antibodies against myelin oligodendrocyte glycoprotein (MOG), has prompted the need for standardized management approaches. Given the current absence of high-level evidence, we aimed to develop consensus-based guidance for the management of MOGAD.Methods: The Korean Society of Neuroimmunology established a task force comprising a panel of 13 experts, and the RAND/UCLA appropriateness methodology was adopted. Definitions were developed for core clinical manifestation, acute stage, relapse, and persistent MOG-IgG seropositivity. Based on extensive review of the literature, initial guidance statements on four key topics were developed. Two rounds of anonymous votes were conducted to achieve consensus on guidance statements, with modifications based on panel input.Results: Comprehensive guidance statements were developed covering MOG antibody assay and diagnosis, acute treatment, and long-term immunotherapy for MOGAD.Conclusion: This guidance is a national formal consensus of MOGAD experts intended to serve as a valuable guide for clinicians managing Korean adults with MOGAD.

show abstract

Novel index, neutrophil percentage (%) is a useful marker for disease activity in MOG antibody-associated disease

Baek

Chung

et al. 2023

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease

Cited by 7 publications

References 42 publications

Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease

Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease

National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Novel index, neutrophil percentage (%) is a useful marker for disease activity in MOG antibody-associated disease

Contact Info

Product

Resources

About